OptimizeRx reaffirms FY2023 prelim revenue >$68-70M; updates 2024 revenue guidance to at least $100M

OptimizeRx Corp

FY2023 preliminary revenue exceeds $68-70M range; adjusted EBITDA in $3-4M range, consistent with prior guidance.
2024 revenue guidance revised to at least $100M due to gross-to-net revenue recognition change for Medicx Health.
2024 adjusted EBITDA guidance unchanged at greater than $11M.
FY2023 earnings call scheduled for March 28, 2024; year-end audit ongoing including Medicx Health and material weakness remediation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

OptimizeRx Corp reported FY2023 results: revenue $68-$70 million. Guidance reaffirmed.

Period: FY2023
Revenue: $68-$70 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

EBITDA guidance remains unchanged, at greater than $11 million for 2024. Based on its preliminary, unaudited review, OptimizeRx estimates FY2023 revenue to exceed the range of $68-$70 million and adjusted EBITDA to be in the range of $3-$4 million, which is consistent with the Company’s previously announced guidance. The estimated revenue and adjusted

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-021461

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.